AstraZeneca shares decline significantly after failure of new heart disease drug trial

AstraZeneca's stock fell by up to 9% after an advanced clinical trial for the drug "Wynova" failed to meet its primary endpoint in treating transthyretin amyloid cardiomyopathy (ATTR-CM). The drug was unable to achieve its main goal of reducing death rates and cardiac events over 140 weeks compared to placebo. However, these results currently do not impact the drug's approval for treating nerve damage conditions. The study findings indicate that adding Wynova did not show a clear statistical benefit in patients already receiving stable protein therapy. Market analysts estimated that the trial's failure has not significantly affected the company's goal of reaching $80 billion in revenue by 2030, but they expressed concern about a decline in the company's management credibility.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل